Giuseppina Maura Francese

Dr. Giuseppina Maura Francese

Cardiology, Azienda di Rilievo Nazionale e di Alta Specializzazione Garibaldi, Catania, Sicilia, Italy
Cardiologist. Cardiology Division, Garibaldi Nesima Hospital...

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2009 in EP Europace
Verified
Journal Article
Open access
PDF file
MBMichele Brignole
Michele Brignole
AUAndrea Ungar
Andrea Ungar
ICIvo Casagranda
Ivo Casagranda
MGMichele Massimo Gulizia
Michele Massimo Gulizia
MLMaurizio Lunati
Maurizio Lunati
FIfor the Syncope Unit Project (SUP) investigators
for the Syncope Unit Project (SUP) investigators
Although an organizational model for syncope management facilities was proposed in the 2004 guidelines of the European Society of Cardiology (ESC), its implementation in clinical practice and its effectiveness are largely unknown. This prospective study enrolled 941 consecutive patients referred to the Syncope Units of nine general hospitals from 15 March 2008 to 15 September 2008. A median of 15 patients per month were examined in each unit, but the five older units had a two-fold higher volume of activity than the four newer ones (instituted <1 year before): 23 vs. 12, P = 0.02. These figures give an estimated volume of 163 and 60 patients per 100 000 inhabitants per year, respectively. Referrals: 60% from out-of-hospital services, 11% immediate and 13% delayed referrals from the Emergency Department, and 16% hospitalized patients. A diagnosis was established on initial evaluation in 191 (21%) patients and early by means of 2.9 ± 1.6 tests in 541 (61%) patients. A likely reflex cause was established in 67%, orthostatic hypotension in 4%, cardiac in 6% and non-syncopal in 5% of the cases. The cause of syncope remained unexplained in 159 (18%) patients, despite a mean of 3.5 ± 1.8 tests per patient. These latter patients were older, more frequently had structural heart disease or electrocardiographic abnormalities, unpredictable onset of syncope due to the lack of prodromes, and higher OESIL and EGSIS risk scores than the other groups of patients. The mean costs of diagnostic evaluation was €209 per outpatient and €1073 per inpatient. The median cost of hospital stay was €2990 per patient. We documented the current practice of syncope management in specialized facilities that have adopted the management model proposed by the ESC. The results are useful for those who wish to replicate this model in other hospitals. Syncope remains unexplained during in-hospital evaluation in more complex cases at higher risk.

22 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FLFabiana Lucà
Fabiana Lucà
MAMaurizio Giuseppe ABRIGNANI
Maurizio Giuseppe ABRIGNANI
IPIris Parrini
Iris Parrini
SFStefania Angela Di Fusco
Stefania Angela Di Fusco
SGSimona Giubilato
Simona Giubilato
MGMichele Massimo Gulizia
Michele Massimo Gulizia
Cardiovascular diseases (CVD) have a lower prevalence in women than men; although, a higher mortality rate and a poorer prognosis are more common in women. However, there is a misperception of CVD female risk since women have commonly been considered more protected so that the real threat is vastly underestimated. Consequently, female patients are more likely to be treated less aggressively, and a lower rate of diagnostic and interventional procedures is performed in women than in men. In addition, there are substantial sex differences in CVD, so different strategies are needed. This review aims to evaluate the main gender-specific approaches in CVD.

24 August 2020 in Journal of Cardiovascular Medicine
Verified
Journal Article
Closed access
FCFurio Colivicchi
Furio Colivicchi
SFStefania Angela Di Fusco
Stefania Angela Di Fusco
PSPietro Scicchitano
Pietro Scicchitano
PCPasquale Caldarola
Pasquale Caldarola
AMAdriano Murrone
Adriano Murrone
DGDomenico Gabrielli
Domenico Gabrielli
The central role of high low-density lipoprotein cholesterol levels in atherosclerotic cardiovascular disease has led to research focused on lipid-lowering agents for cardiovascular risk reduction. Bempedoic acid is an emerging treatment for hypercholesterolemia that has recently been approved for marketing in the United States and Europe. This review focuses on its mechanism of action and summarizes the main preclinical study findings. Furthermore, we report the clinical evidence supporting and guiding its use in hypercholesterolemia management.

1 April 2024 in European Heart Journal Supplements
Verified
Journal Article
Open access
PDF file
FLFabiana Lucà
Fabiana Lucà
DPDaniela Pavan
Daniela Pavan
MGMichele Massimo Gulizia
Michele Massimo Gulizia
MMMaria Teresa Manes
Maria Teresa Manes
MAMaurizio Giuseppe Abrignani
Maurizio Giuseppe Abrignani
FOFabrizio Oliva
Fabrizio Oliva
It has been well assessed that women have been widely under-represented in cardiovascular clinical trials. Moreover, a significant discrepancy in pharmacological and interventional strategies has been reported. Therefore, poor outcomes and more significant mortality have been shown in many diseases. Pharmacokinetic and pharmacodynamic differences in drug metabolism have also been described so that effectiveness could be different according to sex. However, awareness about the gender gap remains too scarce. Consequently, gender-specific guidelines are lacking, and the need for a sex-specific approach has become more evident in the last few years. This paper aims to evaluate different therapeutic approaches to managing the most common women’s diseases.

21 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SGSimona Giubilato
Simona Giubilato
GFGiuseppina Maura Francese
Giuseppina Maura Francese
MMMaria Teresa Manes
Maria Teresa Manes
RRRoberta Rossini
Roberta Rossini
RBRoberta Della Bona
Roberta Della Bona
OFOliva Fabrizio
Oliva Fabrizio
Takotsubo syndrome (TTS), also known as the broken-heart syndrome, is a reversible condition typically observed in female patients presenting for acute coronary syndromes (ACS). Despite its increasing incidence, TTS often remains undiagnosed due to its overlap with ACS. The pathophysiology of TTS is complex and involves factors such as coronary vasospasm, microcirculatory dysfunction, increased catecholamine levels, and overactivity of the sympathetic nervous system. Diagnosing TTS requires a comprehensive approach, starting with clinical suspicion and progressing to both non-invasive and invasive multimodal tests guided by a specific diagnostic algorithm. Management of TTS should be personalized, considering potential complications, the presence or absence of coronary artery disease (CAD), diagnostic test results, and the patient’s clinical course. The current data primarily derive from case series, retrospective analyses, prospective registries, and expert opinions. In recent years, there has been growing recognition of gender differences in the pathophysiology, presentation, and outcomes of TTS. This review provides an updated overview of gender disparities, highlighting the importance of tailored diagnostic and management strategies.

1 February 2024 in Giornale Italiano di Cardiologia
Verified
Journal Article
Closed access
FLFabiana Lucà
Fabiana Lucà
DPDaniela Pavan
Daniela Pavan
MGMichele Massimo Gulizia
Michele Massimo Gulizia
MMMaria Teresa Manes
Maria Teresa Manes
MAMaurizio Giuseppe Abrignani
Maurizio Giuseppe Abrignani
FOFabrizio Oliva
Fabrizio Oliva
In ambito cardiovascolare il sesso influenza fortemente i fattori di rischio, svolgendo un ruolo cruciale nella prevenzione, nella presentazione clinica, nell’iter diagnostico e nel trattamento. Oltre all’importante variabile biologica sessuale, il genere implica un costrutto socio-culturale che ha un impatto sull’accesso alle cure e sulla qualità delle stesse, a causa di molteplici barriere strutturali e istituzionali. Tuttavia, nonostante l’enorme importanza questo tema non trova ancora uno spazio adeguato nella pratica clinica, in cui le differenze basate sul sesso e sul genere hanno scarsa ricaduta, creando disparità nell’assistenza e negli outcome. Diventa essenziale pertanto aumentare la consapevolezza dell’importanza delle influenze del sesso sulla malattie cardiovascolari e sviluppare strategie atte ad eliminare le disparità, raffinando le raccomandazioni delle linee guida che devono essere contestualizzate nella pratica clinica alla luce di tali differenze. In tal senso è fondamentale che le donne vengano inserite nei trial, dal momento che ad oggi rimangano scarsamente rappresentate, e che venga incrementata la rappresentatività delle donne anche tra gli estensori delle linee guida e dei componenti dei board internazionali al fine di garantire una maggiore attenzione su questo importante tema senza che esso tuttavia venga circoscritto ad un interesse femminile ma coinvolga ricercatori e clinici indipendentemente dal sesso.Scopo di questo position paper ANMCO è muovere dei passi in questa direzione, facendo luce sulle differenze di genere emerse dalla letteratura sull’azione di molti farmaci in ambito cardiovascolare, al fine di promuovere un approccio terapeutico sempre più personalizzato che tenga conto anche del sesso e del genere.